# US 2021/0171473 A1 · Oxopiperazine helix mimetics for control of hypoxia-inducible gene expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171473 A1
- Document ID: US20210171473A1
- Status: Published application
- Kind: A1
- Application number: 16/984,041
- Filed: 2020-08-03
- Published: 2021-06-10
- Earliest claimed: 2014-05-21
- Assignees: New York University
- Applicants: New York University
- Inventors: Paramjit S. ARORA; Brooke Bullock LAO; Richard BONNEAU; Kevin DREW
- Web page: https://patentgrep.com/patent/US20210171473A1

## CPC

- C07D 241/08: with oxygen atoms directly attached to ring carbon atoms
- C07D 403/14: containing three or more hetero rings
- A61P 35/00: Antineoplastic agents
- C07C 29/80: by distillation
- C07C 29/88: by treatment giving rise to a chemical modification of at least one compound (chemisorption C07C29/76)
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention relates to oxopiperazines that mimic helix αB of the C-terminal transactivation domain of HIF1α. Also disclosed are pharmaceutical compositions containing these oxopiperazines and methods of using these oxopiperazines (e.g., to reduce gene transcription, treat or prevent disorders mediated by interaction of HIF1α with CREB-binding protein and/or p300, reduce or prevent angiogenesis in a tissue, induce apoptosis, and decrease cell survival and/or proliferation).

## Claims

### Claim 1

An oxopiperazine selected from the group consisting of
(i) Formula IA:
wherein:
R1 is hydrophobic and is an amino acid side chain, OR, SR, an alkyl, or an aryl; wherein R is independently H, an alkyl, or an aryl;
R2 is an amino acid side chain, OR, SR, an alkyl, or an aryl; wherein R is independently H, an alkyl, or an aryl; wherein R2 is either a leucine side chain or longer than a leucine side chain by at least one backbone methylene; and with the proviso that R1 and R2 are not both an aryl;
R3 is hydrophobic and is an amino acid side chain, SR, or an alkyl; wherein R is independently H, an alkyl, or an aryl;
R4 is a hydrogen bond donor, a hydrophobic amino acid side chain, or an amide;
each R6 is independently H, N(R)2, OR, halogen, an alkyl, or an aryl; wherein each R is independently H, an alkyl, or an aryl;
X1 is H, N(R)2, OR, COR′, CO2R′, CONR′, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a peptide of 1 to about 10 amino acid residues, a protecting group for protection of an amine, a solubilizing group, a targeting moiety, or a tag; wherein each R is independently H, an alkyl, or an aryl; and wherein R′ is H, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag; with the proviso that X1 is absent when Z is O or S;
Z is N, O, or S;
A1-W1 is:
and
Y is OR′, N(R′″)2, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, an amino acid, a peptide of 1 to about 10 amino acid residues, a protecting group for protection of a carboxylic acid, a targeting moiety, or a tag; wherein R′ is H, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag; and wherein each R′″ is independently H, CO2R′, CONR′, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag;
and (ii) Formula IB:
wherein:
R0 is hydrophobic and is an amino acid side chain, OR, SR, an alkyl, or an aryl; wherein R is independently H, an alkyl, or an aryl;
R1 and R2 are each independently a solubilizing group, a hydrophobic amino acid side chain, H, N(R)2, OR, SR, halogen, an alkyl, or an aryl; wherein each R is independently H, an alkyl, or an aryl;
R3 is an amino acid side chain, OR, SR, an alkyl, or an aryl; wherein R is independently H, an alkyl, or an aryl; wherein R2 is either a leucine side chain or longer than a leucine side chain by at least one backbone methylene; and with the proviso that R0 and R3 are not both an aryl;
R4 is a hydrogen bond donor, a hydrophobic amino acid side chain, or an amide;
each R6 is independently H, N(R)2, OR, halogen, an alkyl, or an aryl; wherein each R is independently H, an alkyl, or an aryl;
X′ is H, COR′, CO2R′, CONR′, OR′, N(R″)2, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a solubilizing group, a targeting moiety, or a tag; wherein R′ is H, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, an amino acid residue, a peptide of 1 to about 10 amino acid residues, a targeting moiety, or a tag; and wherein each R″ is independently H, CO2R′, CONR′, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag;
A1-W1 is:
and
Y is OR′, N(R′″)2, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, an amino acid, a peptide of 1 to about 10 amino acid residues, a protecting group for protection of a carboxylic acid, a targeting moiety, or a tag; wherein R′ is H, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag; and wherein each R′″ is independently H, CO2R′, CONR′, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag.

### Claim 2 (depends on 1)

The oxopiperazine according to claim 1, wherein the oxopiperazine has a formula of Formula IA.

### Claim 3 (depends on 2)

The oxopiperazine according to claim 2, wherein R1 is OR, SR, a C3-C6 alkyl, an aryl, or a side chain of an amino acid selected from the group consisting of leucine, methionine, and homoleucine; R2 is OR, SR, a C3-C6 alkyl, an aryl, or a side chain of an amino acid selected from the group consisting of norleucine, methionine, leucine, and homoleucine; R3 is SR, a C1-C3 alkyl, or a side chain of an amino acid selected from the group consisting of glycine and alanine; R4 is a side chain of an amino acid selected from the group consisting of glutamine, alanine, valine, asparagine, serine, and homoserine; and Y is OH, OR′, NHR′, NR′2, or NH2.

### Claim 4 (depends on 1)

The oxopiperazine according to claim 1, wherein the oxopiperazine has a formula of Formula IB.

### Claim 5 (depends on 4)

The oxopiperazine according to claim 4, wherein R0 is OR, SR, a C3-C6 alkyl, an aryl, or a side chain of an amino acid selected from the group consisting of leucine, methionine, and homoleucine; R3 is OR, SR, a C3-C6 alkyl, an aryl, or a side chain of an amino acid selected from the group consisting of norleucine, methionine, leucine, and homoleucine; R4 is a side chain of an amino acid selected from the group consisting of glutamine, alanine, valine, asparagine, serine, and homoserine; and Y is OH, OR′, NHR′, NR′2, or NH2.

### Claim 6 (depends on 1)

The oxopiperazine according to claim 1, wherein the oxopiperazine is selected from the group consisting of oxopiperazine helix mimetic (“OHM”) 23, OHM 24, OHM 25, OHM 28, OHM 29, OHM 30, OHM 31.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

A pharmaceutical formulation comprising:
an oxopiperazine according to claim 1 and
a pharmaceutically acceptable vehicle.

### Claim at position 9

9-14. (canceled)

### Claim 15 (depends on 1)

A method of reducing transcription of a gene in a cell, wherein transcription of the gene is mediated by interaction of Hypoxia-Inducible Factor 1α with CREB-binding protein and/or p300, said method comprising:
contacting the cell with an oxopiperazine according to claim 1 under conditions effective to reduce transcription of the gene.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the gene is selected from the group consisting of am-adrenergic receptor, adenylate kinase 3, adrenomedullin, aldolase A, aldolase C, carbonic anhydrase IX, ceruloplasmin, chemokine receptor type 4 (CXCR4, fusin, CD184), c-Met, endothelin-1, enolase 1, erythropoietin, glucose transporter 1, glucose transporter 3, glyceraldehyde-3-phosphate dehydrogenase, heme oxygenase 1, hexokinase 1, hexokinase 2, IGF binding protein 1, IGF binding protein 3, insulin-like growth factor 2, lactate dehydrogenase A, lysyl oxidase, monoamine oxidase isoform A, monoamine oxidase isoform B, nitric oxide synthase 2, p21, p35srg, phosphofructokinase, phosphoglycerate kinase 1, plasminogen activator inhibitor 1, pyruvate kinase M, stromal-derived factor 1, tranferrin receptor, transferrin, transforming growth factor β3, triose phosphate isomerase 1, vascular endothelial growth factor, vascular endothelial growth factor receptor FLT-1, and vascular endothelial growth factor receptor KDR/Flk-1.

### Claim 17 (depends on 1)

A method of treating or preventing in a subject a disorder mediated by interaction of Hypoxia-Inducible Factor 1α with CREB-binding protein and/or p300, said method comprising:
administering to the subject an oxopiperazine according to claim 1 under conditions effective to treat or prevent the disorder.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

A method of reducing or preventing angiogenesis in a tissue, said method comprising:
contacting the tissue with an oxopiperazine according to claim 1 under conditions effective to reduce or prevent angiogenesis in the tissue.

### Claim at position 15

20-21. (canceled)

### Claim 22 (depends on 1)

A method of inducing apoptosis of a cell, said method comprising:
contacting the cell with an oxopiperazine according to claim 1 under conditions effective to induce apoptosis of the cell.

### Claim 23 (depends on 1)

A method of decreasing survival and/or proliferation of a cell, said method comprising:
contacting the cell with an oxopiperazine according to claim 1 under conditions effective to decrease survival and/or proliferation of the cell.

### Claim 24

(canceled)

### Claim 25

An oxopiperazine of Formula IC:
wherein:
R1 is hydrophobic and is an amino acid side chain, OR, SR, an alkyl, or an aryl; wherein R is independently H, an alkyl, or an aryl;
R2 is an amino acid side chain, OR, SR, an alkyl, or an aryl; wherein R is independently H, an alkyl, or an aryl; wherein R2 is either a leucine side chain or longer than a leucine side chain by at least one backbone methylene; and with the proviso that R1 and R2 are not both an aryl;
R3 is hydrophobic and is an amino acid side chain, SR, or an alkyl; wherein R is independently H, an alkyl, or an aryl;
R4 is a hydrogen bond donor or an amide;
R5 is a hydrophobic amino acid side chain;
each R6 is independently H, N(R)2, OR, halogen, an alkyl, or an aryl; wherein each R is independently H, an alkyl, or an aryl;
R7 is a solubilizing group, a hydrophobic amino acid side chain, H, N(R)2, OR, SR, halogen, an alkyl, or an aryl; wherein each R is independently H, an alkyl, or an aryl;
X1 is H, N(R)2, OR, COR′, CO2R′, CONR′, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a peptide of 1 to about 10 amino acid residues, a protecting group for protection of an amine, a solubilizing group, a targeting moiety, or a tag; wherein each R is independently H, an alkyl, or an aryl; and wherein R′ is H, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag; with the proviso that X1 is absent when Z is O or S;
Z is N, O, or S;
each A1-W1 is independently:
and
Y is OR′, N(R′″)2, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, an amino acid, a peptide of 1 to about 10 amino acid residues, a protecting group for protection of a carboxylic acid, a targeting moiety, or a tag; wherein R′ is H, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag; and wherein each R′″ is independently H, CO2R′, CONR′, an alkyl, an aryl, an arylalkyl, a cycloalkyl, a heteroaryl, a targeting moiety, or a tag.

### Claim 26

(canceled)

### Claim 27 (depends on 25)

A pharmaceutical formulation comprising:
an oxopiperazine according to claim 25 and
a pharmaceutically acceptable vehicle.

### Claim 28

(canceled)

### Claim 29 (depends on 25)

A method of reducing transcription of a gene in a cell, wherein transcription of the gene is mediated by interaction of Hypoxia-Inducible Factor 1α with CREB-binding protein and/or p300, said method comprising:
contacting the cell with an oxopiperazine according to claim 25 under conditions effective to reduce transcription of the gene.

### Claim 30

(canceled)

### Claim 31 (depends on 25)

A method of treating or preventing in a subject a disorder mediated by interaction of Hypoxia-Inducible Factor 1α with CREB-binding protein and/or p300, said method comprising:
administering to the subject an oxopiperazine according to claim 25 under conditions effective to treat or prevent the disorder.

### Claim 32

(canceled)

### Claim 33 (depends on 25)

A method of reducing or preventing angiogenesis in a tissue, said method comprising:
contacting the tissue with an oxopiperazine according to claim 25 under conditions effective to reduce or prevent angiogenesis in the tissue.

### Claim at position 28

34-35. (canceled)

### Claim 36 (depends on 25)

A method of inducing apoptosis of a cell, said method comprising:
contacting the cell with an oxopiperazine according to claim 25 under conditions effective to induce apoptosis of the cell.

### Claim 37 (depends on 25)

A method of decreasing survival and/or proliferation of a cell, said method comprising:
contacting the cell with an oxopiperazine according to claim 25 under conditions effective to decrease survival and/or proliferation of the cell.

### Claim 38

(canceled)
